Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

No DFS Benefit With Adjuvant Atezolizumab for High-Risk Urothelial Carcinoma

Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.

 

Advertisement

Advertisement

Advertisement

Advertisement